In disappointing news that broke today, the NINDS-supported Phase III ALS clinical trial of the antibiotic ceftriaxone has been stopped. Pre-clinical studies suggested that ceftriaxone could be a promising treatment for ALS. Unfortunately, the results from the ceftriaxone clinical trial did not meet the efficacy standards set for the trial. Ceftriaxone is currently approved by the FDA for the treatment of bacterial infections.
Click here to read more.Share this: